Designing a new manufacturing processes for plasma proteins to maximise alpha-1 antitrypsin recovery

Food and Bioproducts Processing

Volumn 86, Issue 1, 2008, Pages 65-73

  Kumpalume, Peter ^a   LePage, Christopher ^a   Dalton, Joan ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

A+1 supernatant; Albumin; Alpha 1 antitrypsin; Chelating sepharose; Histrap

Indexed keywords

CHROMATOGRAPHIC ANALYSIS; ETHANOL; FRACTIONATION; PH EFFECTS; PROTEINS;

ALBUMIN; ANTITRYPSIN; CHELATING SEPHAROSE; HISTRAP; SUPERNATANT;

PLASMA APPLICATIONS;

EID: 41849098582     PISSN: 09603085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fbp.2007.10.006     Document Type: Article

References (29)

1. Alkins S.A., and O'Mally P. Should health-care systems pay for replacement therapy in patients with α-1 antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest 117 (2000) 875-880
2. American Thoracic Society Documents. American thoracic society/European respiratory society statement: standards for the diagnosis and management of individuals with alpha-1 antityrpsin deficiency. Am J Respir Crit Care Med 168 (2003) 820-900
3. Basler M.W., and Burrel R. Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responses. Inflammation 7 (1983) 387-400
4. Bauer, S., 2005, Large-scale preparation of alpha-1 proteinase inhibitor and use thereof, WO2005027821.
5. Boaglio A., Bassani G., Pico G., and Nerli B. Features of the milk whey protein partitioning in polyethyleneglycol-sodium citrate aqueous two-phase systems with the goal of isolating human alpha-1 antitrypsin expressed in bovine milk. J Chromatogr B 837 1-2 (2006) 18-23
6. Burnouf, T., 1988, Method for preparation of a concentrate of alpha-1-antitrypsin from a human plasma fraction, and its use as a pharmaceutical, EP0282363.
7. Burnouf T., Constans J., Clerc A., Descamps J., Martinache L., and Goudemand M. Biochemical and biological properties of an a1-antitrpsin concentrate. Vox Sang 52 (1987) 291-297
8. Chen S.X., Hammond D.J., Klos A.M., Wood W.D., Wydick J.E., and Lebing W.R. Chromatographic purification of human alpha 1 proteinase inhibitor from dissolved Cohn fraction IV-1 paste. J Chromatogr A 800 2 (1998) 207-218
9. Chen S.X., Hammond D.J., Lang J.M., and Lebing W.R. Purification of alpha 1 proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography. Vox Sang 74 (1998) 232-241
10. Coan, M.H., 1987, Method of preparing alpha-1-proteinase inhibitor, US4697003.
11. Cohn E.J., Gurd F.R.N., Surgenor D.M., Barnes B.A., Brown R.K., Derouaux G., Gillispie J.M., Kahnr F.W., Lever W.F., Lin C.H., Mittelmann D., Mouton R.F., Schmid K., and Uroma E. A system for the separation of the components of human blood: quantitative procedure for the separation of the protein components of human plasma. J Am Chem Soc 72 (1950) 465-474
12. Dalton, J., Podmore, A. and Kumpalume, P., 2006, Method for the isolation of haptoglobin, WO2006043062.
13. 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160 (1999) 1468-1472
14. D'Souza S., and Ananthakrishnan R. Affinity chromatography in the separation of human alpha 1-antitrypsin (alpha 1-AT) and antithrombin-III (AT-III). Aust J Exp Biol Med Sci 57 3 (1979) 245-250
15. Glaser, C.B., 1982, Method for isolating alpha-1-antitrypsin, EP0067293.
16. Hein R.H., Van Beveren S.M., Shearer M.A., Coan M.H., and Brockway W.J. Production of alpha 1-proteinase inhibitor (human). Eur Respir J Suppl 9 (1990) 16s-20s
17. Kee, S.M. and Cook, P.I., 2004, Method for the purification of alpha-1 antitrypsin, AU2003301108.
18. Kistler P., and Nitschmann Hs. Large scale production of human plasma fractions: eight years experience with the alcohol fractionation procedure of Nitschmann, Kisler and Largier. Vox Sang 7 (1962) 414-424
19. Lebing, W., Chavez, M.D., Ownby, D.W., Trukawinski, S. and Wood, W.D., 2002, Method of preparing alpha-1 proteinase inhibitor, WO0248176.
20. Lomas D.A., Belorgey D., Mallya M., Onda M., Kinghorn K.J., Sharp L.K., Phillips R.L., Page R., Crowther D.C., and Miranda E. Polymerisation underlies alpha1-antitrypsin deficiency, dementia and other serpinopathies. Front Biosci 9 (2004) 2873-2891
21. Mattes, E. and Methiessen, H.P., 2002, Alpha 1-antitrypsin preparation as well as a method for producing the same, US2002082214.
22. Mattes E., Matthiessen H.P., Turecek P.L., and Schwarz H.P. Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity. Vox Sang 81 1 (2001) 29-36
23. McCann K.B., Hughes B., Wu J., Bertolini J., and Gomme P.T. Purification of Tf from Cohn supernatant I using ion-exchange chromatography. Biotechnol Appl Biochem 42 3 (2005) 211-217
24. Moraga F., and Janciauskiene S. Activation of primary human monocytes by the oxidized form of α1-antitrypsin. J Biol Chem 275 11 (2000) 7693-7700
25. Neurath, A.R. and Horowitz, B, 1985, Undenatured virus-free biologically active protein derivatives, EP 0131740.
26. Nita I., Hollander C., Westin U., and Janciauskiene S.-M. Prolastin, a pharmaceutical preparation of purified human α1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res 6 (2005) 12-16
27. Reh G., Nerli B., and Pico G. Isolation of alpha-1-antitrypsin from human plasma by partitioning in aqueous biphasic systems of polyethyleneglycol-phosphate. J Chromatogr B Analyt Technol Biomed Life Sci 780 2 (2002) 389-396
28. The Marketing Research Bureau Inc., 2005, The world wide alpha-1 antitrypsin market, present situation and future prospects 2005-2015, November 2005.
29. Wewers M.A., Casolaro S.E., Sellers S.C., Swayze K.M., McPhaul J.T., Wittes P., and Crystal R.G. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Eng J Med 316 17 (1987) 1055-1062